How China became the new world leader in clinical trials
1. 文件大小不能超过300M, 允许上传文档或压缩包等
2. 请确保上传文献的真实性、完整性，不得对原文做任何修改
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
F Murphy
bmj, 2026
bmj.com
… After investing decades and billions of yuan in becoming a scientific superpower, China
is well placed to benefit from the plight of the US medical research sector. But geopolitical
ructions and local idiosyncrasies could complicate this, writes Flynn Murphy … In
September 2025 the National Medical Products Administration, China’s drug regulator,
announced new rules shortening the review period for certain clinical trial applications to 30
days from 60, matching the US Food and Drug Administration’s 30 day review. But this has …
